Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

ty and efficacy of LX1033 in approximately 360 IBS-d patients. Lexicon also received Fast Track status from the FDA for the development of LX1033 in IBS-d.
  • Other Programs: Lexicon obtained results from Phase 1 studies of  LX2931, an inhibitor of sphingosine-1-phosphate lyase, in patients with rheumatoid arthritis, and LX7101, an inhibitor of LIM domain kinase 2 (LIMK2), in patients with glaucoma.  Both compounds were well-tolerated and showed signals of clinical benefit in the respective studies.
  • Financial ResultsRevenues:  Lexicon's revenues for the three months ended December 31, 2012 decreased 36 percent to $0.2 million from $0.3 million for the corresponding period in 2011. For the year ended December 31, 2012, revenues decreased 41 percent to $1.1 million from $1.8 million for the corresponding period in 2011.

    Research and Development Expenses:  Research and development expenses for the three months ended December 31, 2012 decreased 25 percent to $21.0 million from $28.1 million for the corresponding period in 2011, primarily due to a decrease in external manufacturing, clinical research and development costs. For the year ended December 31, 2012, research and development expenses decreased 10 percent to $82.6 million from $91.8 million for the corresponding period in 2011.

    Increase (Decrease) in Fair Value of Symphony Icon Purchase Liability:  In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations. For the three months ended December 31, 2012, the fair value of the Symphony Icon purchase liability decreased by $0.2 million, compared to an increase of $1.6 million in the corresponding period in 2011. For
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon To Present At The BIO CEO & Investor Conference
    2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    4. Lexicon to Provide Third Quarter 2012 Financial Results
    5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    9. Lexicon to Provide Second Quarter 2012 Financial Results
    10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
    (Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
    (Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
    Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
    ... , ATLANTA, Nov. 30 Amoena USA Corporation, ... the 4th Annual Breast Cancer Survivors Cruise. In 2010, for ... who helped them through their recovery by awarding a cabin ... , As part of the contest, Amoena wants to hear ...
    ... , ... the world,s leading research and advisory firms focusing on pharmaceutical ... market in Russia will grow nine percent annually over the ... This growth will be driven mainly by increased government spending ...
    Cached Medicine Technology:Amoena and Young Survival Coalition Celebrate Breast Cancer Survivors With Contest and Cruise 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3
    (Date:7/12/2014)... Sean Francis, owner of the Kawartha Lakes Fit Body ... clients. He’s also known for his support of local non-profits like ... combine the two and is excited to announce that his ... Girls Club. , The funds are the result of Francis’ 21-Day ... sent out emails and asked his clients to put out the ...
    (Date:7/12/2014)... July 12, 2014 With prom shopping ... manufacturer and retailer, is ready to showcase its new ... new collection of evening dresses in its online shop. ... 67% off) for these elegant gowns. According to the ... end on July 26, 2014. , He says, ...
    (Date:7/12/2014)... (PRWEB) July 12, 2014 Doylestown Hospital ... a variety of men’s health questions. Paddock tackles ... to men, why women live longer than men, and ... Men's Health Made Simple featured on Doylestown Hospital’s ... a hernia at any age. If you notice pain, ...
    (Date:7/12/2014)... A recent article released by Seattle's well known plastic surgeon, ... seeking cosmetic surgical procedures in summer months . ... begins to enliven the rainy Pacific Northwest, many people are ... didn’t work out as much during the winter as they ... of people eager to look their best for their summer ...
    (Date:7/12/2014)... (PRWEB) July 12, 2014 ... score of 4.1 out of 5. This above-average ... have been underpinning buyer negotiation power over the ... analyst Anna Son, “during the period, surging demand ... costs associated with new product development, have placed ...
    Breaking Medicine News(10 mins):Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4
    ... and its partner Hyderabad-based Biological E. Ltd. announced ... a pediatric phase II clinical trial for Intercell’s ... ,The randomized and controlled study aims to demonstrate ... vaccine compared to a locally produced mouse-brain Japanese ...
    ... the U.S. population. Nearly one-third of affected people have ... do not work well. Those who suffer from it ... biofeedback treatment can successfully retrain muscles. ,The biofeedback ... and exercise or another treatment (sham) that included muscle ...
    ... Responding to calls for a fair distribution of bird ... to create a global stockpile of vaccines// for developing ... great importance in the fight against avian influenza, WHO ... The Jakarta Post Thursday. ,Chan met President ...
    ... and Wales have been accused of being institutionally racist. ... although services are pioneers in moving towards equity, they ... challenges of a multi-cultural society. ,The "Count ... Commission, makes grim reading for people of African and ...
    ... during a recent influenza B epidemic in Japan showed ... drugs//, according to a study. ,Two antiviral ... drugs known as neuraminidase inhibitors, have been effective against ... evidence of the emergence of oseltamivir-resistant type A viruses, ...
    ... ruling in Alberta empowers pharmacists to prescribe medicines to ... will be allowed to take a decision on the ... or prescriptions given by doctors. ,Though this ... about the ability of the pharmacists to diagnose medical ...
    Cached Medicine News:Health News:Biofeedback Treats One Type Of Chronic Constipation 2Health News:Biofeedback Treats One Type Of Chronic Constipation 3Health News:Chances of Tackling Racism in Mental Health Care is Still Remote 2Health News:Study Suggests Some Drug Resistance to Influenza B Medications 2
    ... is a low profile implantable bipolar ... stimulation of either the atrium (preformed ... model). All ZY leads are supplied ... used to extend/retract the fixation helix ...
    ... are small profile endocardial permanent pacing leads ... lead body size of only 4.8 F ... F, the Physique lead is the smallest ... in both straight and pre-formed J configurations, ...
    Used with Temporary Myocardial Heartwires....
    Used with permanent pacing leads....
    Medicine Products: